




ХИДРОНАФТАЦЕНОВИ АНТИБИОТИЦИ




Naftacene




1,4,4a,5,5a,6,11,12a-octahydronaftacene




Tetracyclines: Gen. struct.






Стабилност в кисела среда

pH=2: Дехидратация и ароматизация на пръстен C (R₆=OH)



Стабилност в кисела среда

pH 2-6: Епимеризация при C-4




установява се равновесие от:


- > 2/3 тетрациклин и
- > 1/3 епитетрациклин

Стабилност в алкална среда

pH 7.5 : Прегрупиране до изотетрациклин (R₆=OH)




Хелатообразуване



- Механизъм: Свързват се с 30S рибозомалната субединица, чрез вкл. в комплекс на Mg²⁺; блокират протеиновия синтез
- Широк спектър на действие (вкл. и срещу някои щамове гъбички, вируси и протозои).
- Бактериостатичен ефект.
- Атакува нормалната микрофлора в GI тракт (благоприятства *candida* инфекции.)


STRUCTURE OF TETRACYCLINES



	R ₁	R ₂	R ₃	R ₄
Tetracycline	H	CH ₃	OH	H
Chlortetracycline	Cl	CH ₃	OH	H
Oxytetracycline	H	CH ₃	OH	OH
Demeclocycline	Cl	H	OH	H
Methacycline	H	CH ₂		OH
Doxycycline	H	H	CH ₃	OH
Minocycline	N(CH ₃) ₂	H	H	H


Tetracyclin

Isolation from *Streptomyces* sp.
Semisynth from chlorotetracycline more effective
(low bioavailability)




Doxycyclin

Not OH i 6-pos. More stable in water solution (also mixture).
Longer $t_{1/2}$, good oral absorb.
Semisynth oxytetracycline.




Lymecycline


More water sol., pro-drug.
Semisynth from tetracycline



R_5 -H
 R_6 -OH
 R_2 -CH₂NHCH₂NH(CH₂)₄CH(NH₂)CO₂H






Rolitetracycline




Противопоказания и взаимодействия с други лекарства

- Взаимодействат с антиацидни лекарствени вещества съдържащи йони на дву- и тривалентни метали, както и с някои храни – напр. мляко.
- Засилват действието на кумариновите производни защото потискат чревната микрофлора образуваща вит. К
- Могат, макар и рядко да предизвикат алергични реакции на кожата.
- Преминават през плацентарната бариера и се отлагат в костите на плода и забавят растежа му. Затова не бива да се прилагат през периода на бременността и при новородени до 3-годишна възраст.
- Противопоказни са при бъбречна и чернодробна недостатъчност.


МАКРОЛИДНИ АНТИБИОТИЦИ



Z1
кладиноза



Z2
дезозамин




Z3
фуразамин

- Isolated from *Streptomyces* sp.
- Relatively narrow spectrum, mainly G+. Low tox.
- Binds to 50S part of ribosome, inhib. Protein synth.


Structure / Activity:

- Macrolaktone (14-16-ring, smaller than antimycotic polyenes)
- Keto function
- No unsat. in lactone ring (spiramycin - dien) ? antimycotic polyenes
- Amino sugar


при pH ≈ 2.4 – 4 образуват полуацетали и ацетали чрез вътрешномолекулна “гликозидна” връзка между функционалните групи на 7-мо и 10-то място и 10-то и 13-то място. Макролактонът обаче е стабилен в кисела среда.



Erythromycin




Clarithromycin




Increased stability acidic media
No intramolec. hemikatalisation

Increased stabil., bioavailability,
less side effects
Somewhat more broad spectrum

Oleandomycin




Spiramycin (Rovamycin)



Isolated from *Streptomyces ambofaciens*.
G+.

R= H: Spiramycin I
R=COCH₃: Spiramycin II
R=COCH₂CH₃: Spiramycin III


Azitromycin



Increased stability acidic media
No intramolec. hemikatalisation


Increased stabil., bioavail.
More active G- less active G+

Telitromycin





Increased stability acidic media
No intramolec. hemikatalisation
Improved ribosome binding, less resistans
Increased ribosome affinity

ПОЛИЕНОВИ АНТИБИОТИЦИ




АМИНОГЛИКОЗИДНИ АНТИБИОТИЦИ

- Broad spectrum
- Toxic
- Inhib. protein synthesis
- -N o absorb. from GI, local treatment infect. GI tract.
- Systemic infections – parenteral adm.





- Basic, water soluble salts phys. pH
- -Glykosides (= acetals) stable acidic media because of protonated amino subst.




Aminoglycosides


- Spectrum
 - Gram-negative bacilli, P. aeruginosa (use with anti-pseudomonas penicillins)
- Resistance
 - Antibiotic modifying agents cause antibiotics to be unable to bind to the ribosome
- Toxicity
 - Nephrotoxic (trough)
 - Ototoxic (concentrated in perilymph, corresponds with prolonged therapy and peak levels)
 - Neuromuscular blockade (think of this in Myasthenia Gravis)








Gentamicin




Gentamicin C₁
Gentamicin C₂
Gentamicin C_{1a}

$R_1 = R_2 = CH_3$
 $R_1 = CH_3, R_2 = H$
 $R_1 = R_2 = H$

Amikacin




Kanamycin




Kanamycin A	$R = NH_2$	$R' = OH$
Kanamycin B	$R = NH_2$	$R' = NH_2$
Kanamycin C	$R = OH$	$R' = NH_2$

TOBRAMYCIN



NEOMYCIN C




Lincomycines

- Sulfur cont. antibiotics from *Streptomyces lincolnensis*;
- Naturally occurring: Linkomycin (not in N), more active semisynth der.
- Inhib protein synth, binds to 50S part of ribosome

Clindamycin

Dalactin® Dalactin® Clindamycin®.


Semisynth from linkomycin







R= H, R'=Cl: *Clindamycin*

R=OH, R'=H: *Linkomycin*.

АРОМАТНИ НИТРОСЪЕДИНЕНИЯ
Chloramfenicol





- > Isol. 1.time *Streptomyces venezuelae* (1947), later found in several microorg.
- > Broad spectrum. Inhib. Protein synth., mech. Not fully understood.
- > Rel. tox. (damage bone marrow – anemia, leukemia), seldom used systemically.
- > Simple structure – total synthesis.



БЕНЗОФУРАНИ


Griseofulvine




ПЕПТИДНИ АНТИБИОТИЦИ


Polymyxins


- > Low oral avail.; local admin. or. infusion/injektion.
- > Often high tox (kidneys).
- > D-amino acids and other rare AA.




Polymyxin B ₁	R = (+)-6-methyloctanoyl	X = Phe	Y = Leu	Z = DAB
B ₂	R = 6-methylheptanoyl	X = Phe	Y = Leu	Z = DAB
D ₁	R = (+)-6-methyloctanoyl	X = Leu	Y = Thr	Z = D-Ser
D ₂	R = 6-methylheptanoyl	X = Leu	Y = Thr	Z = D-Ser







Inhibition of peptidoglycan cross-linking by Beta-Lactams and Vancomycin and mechanisms of resistance.



1. Transpeptidase enzyme binds to D-Ala-D-Ala for cross-linking.
2. Beta-lactam antibiotic binds to transpeptidase inhibiting cross-linking.
3. Vancomycin binds to D-Ala-D-Ala preventing binding of enzyme.
4. Beta-lactamase cleaves beta-lactam antibiotic.
5. Changing terminal D-Ala to D-Lactate prevents vancomycin binding.

Bacitracin

Isol. *Bacillus subtilis*.

Mixt of struct


(Bacitracin A, A1, B, C, D, E, F1, F2, F3 and G)

Bacitracin A main comp. Bacimycin.

Mainly G+.

Inhib. Synth. mukopeptide in cell wall.

Requires Zn²⁺ for activity



Други



Fusidinic acid

> Narrow spectrum: G+; *Staphylococcus aureus*, *corynebacteria*

Streptococcus sp.(weak effect).

> Inhib. Protein synth.

> No cross resist.



Mupirocin

> Major component of the pseudomonic acids, an antibiotic complex produced by *Pseudomonas fluorescens*.

